Home > Oncology > WCLC 2018 > No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype

No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype

Positive PFS findings from phase 2 of the global randomised LUME-Meso trial did not carry through to phase 3 outcomes as the study failed to meet the primary endpoint of PFS in patients with malignant pleural mesothelioma (MPM) treated with nintedanib plus pemetrexed/cisplatin. IASLC president Prof. Giorgio Scagliotti (University of Turin and San Luigi Hospital, Italy) presented the findings [13].

Nintedanib is a multikinase inhibitor that targets VEGF receptors 1–3, PDGF receptors α/β, FGF receptors 1–3, and Src and Abl kinase signalling [14, 15]. Combined with pemetrexed/ cisplatin, it improved PFS (HR 0.56) with a trend toward prolonged OS (HR 0.77) in phase 2 of the LUME-Meso trial [16]. The effect was particularly evident in patients with epithelioid histology (PFS HR 0.51; OS HR 0.70).

The randomised LUME-Meso study enrolled 458 patients with treatment-naïve, histologically confirmed, unresected epithelioid MPM. Patients received up to 6 cycles of pemetrexed (...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on